Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists

Bin Liu, Carrie H. Croy, Stephen A. Hitchcock, Jennifer R. Allen, Zhigang Rao, David Evans, Mark G. Bures, David L. McKinzie, Marla Leigh Watt, G. Stuart Gregory, Marvin M. Hansen, Paul J. Hoogestraat, James A. Jamison, Fese M. Okha-Mokube, Robert Stratford Jr., William Turner, Frank Bymaster, Christian C. Felder

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimer's disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms. The high homology within the acetylcholine binding domain of this family however has made receptor-selective ligand development challenging. This work presents the synthesis scheme, pharmacokinetic and structure-activity-relationship study findings for M1-selective ligand, LY593093. Pharmacologically the compound acts as an orthosteric ligand. The homology modeling work presented however will illustrate that compound binding spans from the acetylcholine pocket to the extracellular loops of the receptor, a common allosteric vestibule for the muscarinic protein family. Altogether LY593093 represents a growing class of multi-topic ligands which interact with the receptors in both the ortho- and allosteric binding sites, but which exert their activation mechanism as an orthosteric ligand.

Original languageEnglish (US)
Pages (from-to)4158-4163
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume25
Issue number19
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Muscarinic Agonists
N-(6-((1-((4-fluorobenzyl)(methyl)amino)ethylidene))amino)-2-hydroxy-2,3-dihydro-1H-inden-1-ylbiphenyl-4-carboxamide
Cholinergic Agents
Ligands
Acetylcholine
Muscarinic M1 Receptors
Allosteric Site
Neurobehavioral Manifestations
Pharmacokinetics
Networks (circuits)
Drug Delivery Systems
Structure-Activity Relationship
Prosencephalon
Basal Ganglia
Alzheimer Disease
Chemical activation
Binding Sites
Proteins

Keywords

  • Alzheimers disease
  • Drug discovery
  • Multi-topic ligand
  • Muscarinic receptor
  • Structureactivity-relationship

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists. / Liu, Bin; Croy, Carrie H.; Hitchcock, Stephen A.; Allen, Jennifer R.; Rao, Zhigang; Evans, David; Bures, Mark G.; McKinzie, David L.; Watt, Marla Leigh; Stuart Gregory, G.; Hansen, Marvin M.; Hoogestraat, Paul J.; Jamison, James A.; Okha-Mokube, Fese M.; Stratford Jr., Robert; Turner, William; Bymaster, Frank; Felder, Christian C.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 25, No. 19, 01.10.2015, p. 4158-4163.

Research output: Contribution to journalArticle

Liu, B, Croy, CH, Hitchcock, SA, Allen, JR, Rao, Z, Evans, D, Bures, MG, McKinzie, DL, Watt, ML, Stuart Gregory, G, Hansen, MM, Hoogestraat, PJ, Jamison, JA, Okha-Mokube, FM, Stratford Jr., R, Turner, W, Bymaster, F & Felder, CC 2015, 'Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists', Bioorganic and Medicinal Chemistry Letters, vol. 25, no. 19, pp. 4158-4163. https://doi.org/10.1016/j.bmcl.2015.08.011
Liu, Bin ; Croy, Carrie H. ; Hitchcock, Stephen A. ; Allen, Jennifer R. ; Rao, Zhigang ; Evans, David ; Bures, Mark G. ; McKinzie, David L. ; Watt, Marla Leigh ; Stuart Gregory, G. ; Hansen, Marvin M. ; Hoogestraat, Paul J. ; Jamison, James A. ; Okha-Mokube, Fese M. ; Stratford Jr., Robert ; Turner, William ; Bymaster, Frank ; Felder, Christian C. / Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists. In: Bioorganic and Medicinal Chemistry Letters. 2015 ; Vol. 25, No. 19. pp. 4158-4163.
@article{2892884ffef448f3acd73940660c3174,
title = "Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists",
abstract = "The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimer's disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms. The high homology within the acetylcholine binding domain of this family however has made receptor-selective ligand development challenging. This work presents the synthesis scheme, pharmacokinetic and structure-activity-relationship study findings for M1-selective ligand, LY593093. Pharmacologically the compound acts as an orthosteric ligand. The homology modeling work presented however will illustrate that compound binding spans from the acetylcholine pocket to the extracellular loops of the receptor, a common allosteric vestibule for the muscarinic protein family. Altogether LY593093 represents a growing class of multi-topic ligands which interact with the receptors in both the ortho- and allosteric binding sites, but which exert their activation mechanism as an orthosteric ligand.",
keywords = "Alzheimers disease, Drug discovery, Multi-topic ligand, Muscarinic receptor, Structureactivity-relationship",
author = "Bin Liu and Croy, {Carrie H.} and Hitchcock, {Stephen A.} and Allen, {Jennifer R.} and Zhigang Rao and David Evans and Bures, {Mark G.} and McKinzie, {David L.} and Watt, {Marla Leigh} and {Stuart Gregory}, G. and Hansen, {Marvin M.} and Hoogestraat, {Paul J.} and Jamison, {James A.} and Okha-Mokube, {Fese M.} and {Stratford Jr.}, Robert and William Turner and Frank Bymaster and Felder, {Christian C.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.bmcl.2015.08.011",
language = "English (US)",
volume = "25",
pages = "4158--4163",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "19",

}

TY - JOUR

T1 - Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M1 agonists

AU - Liu, Bin

AU - Croy, Carrie H.

AU - Hitchcock, Stephen A.

AU - Allen, Jennifer R.

AU - Rao, Zhigang

AU - Evans, David

AU - Bures, Mark G.

AU - McKinzie, David L.

AU - Watt, Marla Leigh

AU - Stuart Gregory, G.

AU - Hansen, Marvin M.

AU - Hoogestraat, Paul J.

AU - Jamison, James A.

AU - Okha-Mokube, Fese M.

AU - Stratford Jr., Robert

AU - Turner, William

AU - Bymaster, Frank

AU - Felder, Christian C.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimer's disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms. The high homology within the acetylcholine binding domain of this family however has made receptor-selective ligand development challenging. This work presents the synthesis scheme, pharmacokinetic and structure-activity-relationship study findings for M1-selective ligand, LY593093. Pharmacologically the compound acts as an orthosteric ligand. The homology modeling work presented however will illustrate that compound binding spans from the acetylcholine pocket to the extracellular loops of the receptor, a common allosteric vestibule for the muscarinic protein family. Altogether LY593093 represents a growing class of multi-topic ligands which interact with the receptors in both the ortho- and allosteric binding sites, but which exert their activation mechanism as an orthosteric ligand.

AB - The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimer's disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms. The high homology within the acetylcholine binding domain of this family however has made receptor-selective ligand development challenging. This work presents the synthesis scheme, pharmacokinetic and structure-activity-relationship study findings for M1-selective ligand, LY593093. Pharmacologically the compound acts as an orthosteric ligand. The homology modeling work presented however will illustrate that compound binding spans from the acetylcholine pocket to the extracellular loops of the receptor, a common allosteric vestibule for the muscarinic protein family. Altogether LY593093 represents a growing class of multi-topic ligands which interact with the receptors in both the ortho- and allosteric binding sites, but which exert their activation mechanism as an orthosteric ligand.

KW - Alzheimers disease

KW - Drug discovery

KW - Multi-topic ligand

KW - Muscarinic receptor

KW - Structureactivity-relationship

UR - http://www.scopus.com/inward/record.url?scp=84945482197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945482197&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.08.011

DO - 10.1016/j.bmcl.2015.08.011

M3 - Article

VL - 25

SP - 4158

EP - 4163

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 19

ER -